Tuesday 13 October 2026
Export ARVN’s income statement to Excel — free account
Arvinas, Inc.
ARVN Healthcare Biotechnology
Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 1,014.7%, EPS grew 410.7%, free cash flow grew 49.8% and total debt fell 40.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.14
0.31
−4.16%
Follow ARVN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 63.92 |
P/S ratio |
2.00 | 3.20 | 7.59 | 1.70 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(10.55) | (27.66) | (9.80) | (11.15) | |
P/B ratio |
1.11 | 1.94 | 1.75 | 0.96 | |
Price to Tangible BV |
1.11 | 1.94 | 1.75 | 0.96 | |
EV/Sales |
(0.52) | 0.60 | 0.73 | (0.09) | |
EV/EBITDA |
1.53 | 0.00 | 0.00 | 1.56 | |
EV/Operating CF |
0.50 | (0.57) | (0.26) | 0.13 | |
EV/FCF |
0.49 | (0.57) | (0.25) | 0.13 | |
Quick Ratio |
5.62 | 4.85 | 5.36 | 7.54 | |
Current Ratio |
5.70 | 4.92 | 5.44 | 7.91 | |
Net Debt/EBITDA |
17.42 | 9.06 | 9.59 | (3.40) | |
Debt/Assets |
0.05% | 0.06% | 0.05% | 0.04% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.31 | 0.29 | 0.11 | 0.40 | |
Operating CF/Net income |
1.68 | 0.45 | 1.20 | (0.29) | |
Capex/Depreciation |
0.07 | 0.20 | 4.33 | (0.07) | |
Research and Development Expense of Revenue |
154.42% | 643.16% | 386.54% | 21.07% | |
Selling, General and Administrative Expense of Revenue |
50.12% | 242.11% | 122.44% | 9.61% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
24.34% | 89.47% | 77.56% | 2.36% | |
Graham Net Nets |
0.88 | 0.50 | 0.55 | 1.00 | |
Graham Number |
0.00 | 0.00 | 0.00 | 5.04 | |
Earnings Yield |
(9.51%) | (10.79%) | (31.32%) | 1.56% | |
Free Cash Flow Yield |
(52.83%) | (32.79%) | (37.87%) | (38.78%) | |
Revenue per Share |
0.57 | 0.13 | 0.24 | 3.85 | |
Operating CF per Share |
(0.81) | (0.43) | (1.08) | (0.75) | |
Capex per Share |
0.00 | 0.00 | (0.02) | 0.00 | |
Free Cash Flow per Share |
(0.81) | (0.43) | (1.10) | (0.75) | |
Cash per Share |
10.76 | 9.67 | 9.61 | 8.76 | |
Shareholders Equity per Share |
7.71 | 6.12 | 6.04 | 8.68 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.71 | 6.12 | 6.04 | 8.68 | |
Free Cash Flow |
(59.20) | (30.60) | (70.50) | (48.50) | |
Working Capital |
681.40 | 558.20 | 514.80 | 569.70 | |
Capital Expenditures |
(0.10) | (0.20) | (1.30) | (0.20) | |
Net Current Asset Value |
546.40 | 416.70 | 370.00 | 539.30 | |
EV/EBIT |
1.59 | 0.00 | 0.00 | 1.54 | |
Capex to Sales |
0.00 | 0.02 | 0.08 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
20.80 | 10.05 | 7.40 | 32.70 | |
Average Payables |
65.70 | 70.65 | 66.70 | 52.65 | |
Average Assets |
1,005.70 | 904.65 | 824.30 | 792.20 | |
Average Common Equity |
575.20 | 497.80 | 523.45 | 585.75 |
Columns are period end dates